|
|
|
|
Germline Testing for DNA Repair Mutations in Prostate Cancer: Who, When and How? |
Veda N. Giri, MD
|
Understanding the role of germline testing in PCa is now critical to urologic and oncology practice for this disease. Here, we will address who should be considered for germline testing, when germline testing may influence treatment and management, and how to implement germline testing involving provider practices and genetic counseling. |
|
|
|
|
|
|
|
|
PARP Inhibitors - A Breakthrough in Targeted Therapies for Prostate Cancer |
Arpit Rao, MBBS |
In this review, Arpit Rao and Charles Ryan summarize the current indications for PARP inhibitor monotherapies and combination(s), review data from clinical trials in prostate cancer, discuss management of commonly encountered side effects, and highlight exciting clinical research on expanding the role of PARP inhibitors in prostate cancer. |
|
|
|
|
|
|
|
|
What Are the Most Common Genomic Aberrations Seen in DNA Damage Response (DDR) Pathways in Advanced Prostate Cancer?
|
Patrick G. Pilié, MD
|
Men with advanced prostate cancer have a 10-15% risk of carrying a hereditary, or germline, variant in a DNA damage response gene, as previously discussed. Pathogenic or deleterious variants in these same DDR genes can also be found at the somatic, or tumor-associated level, in up to 25% of metastatic castrate-resistant prostate cancer.
|
|
|
|
|
|
|
PARP Inhibitors, Prostate Cancer and a Promise Fulfilled |
Charles Ryan, MD |
June 26, 2020, marked the 20th anniversary of the publication of the first working draft from the Human Genome Project. At a special White House event to commemorate the results of this 10-year public effort (it was really more like 50 years since the discovery of DNA, but I digress), then-President Bill Clinton called the project “the most wondrous map ever created by humankind”, and touted its promise to detect, prevent, and treat disease. |
|
|
|
|
|
|
|
|
|
|
|
STATE-OF-THE-INDUSTRY VIDEOS BY LEADING EXPERTs
|
|
|
|
|
|
DNA Repair and PARP Inhibitor Therapy in Prostate Cancer
|
Charles Ryan, MD, Veda N. Giri, MD, Patrick G. Pilié, MD, Arpit Rao, MD, MBBS
Charles Ryan is joined by Veda Giri, Patrick Pilié, and Arpit Rao for a roundtable discussion on DNA repair and Poly (ADP-ribose) polymerase (PARP) inhibitor therapy in prostate cancer.
|
|
|
|
|
|
|
|
|
|
|
|